Gilmore O'Neill's most recent trade in Sarepta Therapeutics Inc was a trade of 15,000 Common Stock done . Disclosure was reported to the exchange on Feb. 28, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics Inc | Gilmore O'Neill | EVP, R&D & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2021 | 15,000 | 28,546 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Gilmore O'Neill | EVP, R&D & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.97 per share. | 28 Feb 2021 | 524 | 13,546 (0%) | 0% | 87.0 | 45,572 | Common Stock |